An interventional study of blood sampling and saliva sampling in Glioblastoma (GBM), sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-03-16.
Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Glioblastoma by Assistance Publique - Hôpitaux de Paris — 2 open to participants now, 2 under way, none of them phase 3. Glioblastoma · Assistance Publique - Hôpitaux de Paris.
Among the 11 studies in Glioblastoma by Assistance Publique - Hôpitaux de Paris, this one is the only one that started in 2026, is the only one with no phase, and was the 11th registered.
2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →2 of the 11 studies in Glioblastoma by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–75
By country, each count listing its studies:
Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 2
First in 2001; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is above the median of 36 across 1,758 interventional studies indexed under Glioblastoma.
Median enrollment 70 across the 9 interventional studies, 160 across the 1 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Glioblastoma by Assistance Publique - Hôpitaux de Paris, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Glioblastoma (GBM) is the most common and most aggressive primary brain cancer in adults. GBM is more common in men than in women, with a male-to-female ratio of 1.6. Furthermore, being male is associated with a poorer prognosis. These data suggest that sex and/or sexual hormones and more specifically androgens may play a role in the initiation, the growth, and the resistance to treatments of GBM.
Glioblastoma (GBM) is the most common and most aggressive primary brain tumor in adults, with an annual incidence in France of approximately 2,500-3,500 new cases. Despite intensive multimodal treatment, the median overall survival remains less than 18 months.
For reasons that are not yet fully understood, GBM occurs more frequently in men than in women, with a male-to-female ratio of approximately 1.6. Moreover, male sex appears to be associated with a poorer prognosis, as men diagnosed with GBM tend to have shorter survival compared with women. Importantly, such sex-based differences are not restricted to GBM; with few exceptions, they are also observed in most non-hormone-dependent systemic cancers.
These epidemiological and clinical observations suggest that sex and/or sex steroid hormones-particularly androgens-may contribute to GBM biology. The effects of androgens are primarily mediated through their binding to the androgen receptor (AR). Preliminary data indicate that AR is expressed not only by GBM tumor cells but also by cells within the tumor microenvironment, especially cells of the myeloid lineage, including microglia and tumor-associated macrophages.
In addition, some studies have shown that certain GBM cells are capable of producing dihydrotestosterone. Taken together, these findings support a potential role for androgen signaling in modulating both tumor cells and the immune microenvironment in GBM. They also provide a rationale for evaluating anti-androgen therapies, either alone or in combination with other treatment modalities, including immunotherapies, in patients with GBM.
Further support for this hypothesis comes from studies in systemic cancers. In prostate cancer, for example, anti-androgen therapy has been shown to increase cytotoxic T lymphocyte infiltration. Combinations of hormone therapy and immunotherapy have been tested in preclinical models, demonstrating reduced androgen-induced immunosuppression and enhanced sensitivity to immune checkpoint inhibitors, an approach currently being explored in clinical trials. Moreover, in melanoma-a non-hormone-dependent cancer such as GBM-AR silencing increases cytotoxic T-cell infiltration, reduces regulatory T-cell infiltration, and decreases the expression of immune inhibitory molecules such as LAG-3 and PD-1.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult men and women with GBM who are being treated in the neuro-oncology department at La Pitié-Salpêtrière Hospital.
Other: blood sampling · Other: saliva sampling · Other: stool sampling · Other: Tumor sampling
Additional blood samples (in addition to those taken as part of treatment) will be taken from patients at T1 (before any medical treatment) and at T2 (one month after the end of concomitant chemoradiotherapy). These samples, totaling 6 to 8 mL, will be taken between 9 a.m. and 11 a.m. (this time slot allows patients to normalize their circadian rhythm)
During these same visits at T1 and T2, a saliva sample will be collected using Salivette® Cortisol saliva collection devices (UGAP ref.: 2745674)
During these same visits at T1 and T2, a stool sample will be collected by the patient using the kit (Stool Sample Collection Kit with Stool Catcher, Canvax)
At the time of surgery performed as part of treatment (before T1), tumor tissue from the surgical waste will be collected.
Mean expression of AR, ER, and other hormone signaling pathway genes in the tumor
Expression of AR, ER, and other hormone signaling pathway genes using tumor RNA sequencing data
Time frame: Baseline: Before any treatment; 4 to 6 weeks after completion of the concurrent radiochemotherapy
Mean of Percentage of immunosuppressive cells measured at T1 and T2 in the blood and tumor
Percentage of immunosuppressive cells measured at T1 and T2 in the blood and tumor using spectral cytometry
Time frame: Baseline: Before any treatment; 4 to 6 weeks after completion of the concurrent radiochemotherapy
Profile of immunosuppressive cytokines in the tumor
Profile of immunosuppressive cytokines in the tumor (quantification of a panel of cytokines)
Time frame: Baseline: Before any treatment; 4 to 6 weeks after completion of the concurrent radiochemotherapy
Mean of the Proportion of intratumoral immune cells
Proportion of intratumoral immune cells via the deconvolution of tumor RNA sequencing data
Time frame: Baseline: Before any treatment; 4 to 6 weeks after completion of the concurrent radiochemotherapy
Plan to share: Yes — The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients. Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.
Supporting information: Study protocol, Informed consent form
Time frame: Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor
Access criteria: Researchers who provide a methodologically sound proposal.
No publications or documents are linked to this record.
Start is estimated for Apr 2026; primary completion for Apr 2030, 48 months later.
Of 133 non-industry interventional studies with no phase under Glioblastoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 97. This study's planned 48 months is below that.
Counting every sponsor, half of 151 studies reached it within 54 months; a quarter within 36 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →